SAB Biotherapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 8, 2024
SABS$3.07-1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes In Stockholders’ Equity
| Common stock · Preferred Stock · Treasury Stock | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | AdditionalPaid-In Capital | Shares | Amount | AccumulatedDeficit | Accumulated Other Comprehensive Income (Loss) | Total Stockholders’Equity | |
| Balance at December 31, 2022 | 5,093,927 | $510 | — | $— | $84,448,633 | (54,665) | $(5,521,246) | $(47,869,755) | $— | $31,058,142 |
| Issuance of common stock for exercise of stock options | 350 | — | — | — | 1,890 | — | — | — | — | 1,890 |
| Professional fees settled with warrants | — | — | — | — | 93,530 | — | — | — | — | 93,530 |
| Stock-based compensation | — | — | — | — | 602,780 | — | — | — | — | 602,780 |
| Net loss | — | — | — | — | — | — | — | (7,353,820) | — | (7,353,820) |
| Balance at March 31, 2023 | 5,094,277 | 510 | — | — | 85,146,833 | (54,665) | (5,521,246) | (55,223,575) | — | 24,402,522 |
| Issuance of common stock for settlement of accrued liabilities and professional fees | 191,689 | 19 | — | — | 1,549,982 | — | — | — | — | 1,550,001 |
| Stock-based compensation | — | — | — | — | 644,815 | — | — | — | — | 644,815 |
| Net loss | — | — | — | — | — | — | — | (6,880,886) | — | (6,880,886) |
| Balance at June 30, 2023 | 5,285,966 | $529 | — | $— | $87,341,630 | (54,665) | $(5,521,246) | $(62,104,461) | $— | $19,716,452 |
| Balance at December 31, 2023 | 9,280,159 | 929 | 42,236 | 5 | 152,856,874 | (54,665) | (5,521,246) | (90,063,541) | 26,420 | 57,299,441 |
| Stock-based compensation | — | — | — | — | 617,445 | — | — | — | — | 617,445 |
| Issuance of common stock for exercise of stock options | 3,780 | — | — | — | 20,412 | — | — | — | — | 20,412 |
| Net loss | — | — | — | — | — | — | — | (5,025,745) | — | (5,025,745) |
| Foreign currency translation | — | — | — | — | — | — | — | — | (33,807) | (33,807) |
| Unrealized gain (loss), change in fair value of available-for-sale securities | — | — | — | — | — | — | — | — | (56,061) | (56,061) |
| Balance at March 31, 2024 | 9,283,939 | 929 | 42,236 | 5 | 153,494,731 | (54,665) | (5,521,246) | (95,089,286) | (63,448) | 52,821,685 |
| Stock-based compensation | — | — | — | — | 601,433 | — | — | — | — | 601,433 |
| Net loss | — | — | — | — | — | — | — | (7,335,455) | — | (7,335,455) |
| Foreign currency translation | — | — | — | — | — | — | — | — | 19,632 | 19,632 |
| Unrealized gain (loss), change in fair value of available-for-sale securities | — | — | — | — | — | — | — | — | 12,463 | 12,463 |
| Balance at June 30, 2024 | 9,283,939 | $929 | 42,236 | $5 | $154,096,164 | (54,665) | $(5,521,246) | $(102,424,741) | $(31,353) | $46,119,758 |
See accompanying notes to the condensed consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.